Moreover, there is increasing evidence that the activation of the IDO1-driven Trp catabolic pathway has clinical implication for humans: shown for sepsis or trauma [32], [33], depression [34], [35] and schizophrenia [34]. Here, IDO1 is linked to depressive symptom measurement.